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ABSTRACT Mycobacterium tuberculosis nicotinamidase-pyrazinamidase (PZAse) is a
metalloenzyme that catalyzes conversion of nicotinamide-pyrazinamide to nicotinic
acid-pyrazinoic acid. This study investigated whether a metallochaperone is required
for optimal PZAse activity. M. tuberculosis and Escherichia coli PZAses (PZAse-MT and
PZAse-EC, respectively) were inactivated by metal depletion (giving PZAse-MT–Apo
and PZAse-EC–Apo). Reactivation with the E. coli metallochaperone ZnuA or Rv2059
(the M. tuberculosis analog) was measured. This was repeated following proteolytic
and thermal treatment of ZnuA and Rv2059. The CDC1551 M. tuberculosis reference
strain had the Rv2059 coding gene knocked out, and PZA susceptibility and the pyr-
azinoic acid (POA) efﬂux rate were measured. ZnuA (200 M) achieved 65% PZAse-
EC–Apo reactivation. Rv2059 (1 M) and ZnuA (1 M) achieved 69% and 34.3%
PZAse-MT–Apo reactivation, respectively. Proteolytic treatment of ZnuA and Rv2059
and application of three (but not one) thermal shocks to ZnuA signiﬁcantly reduced
the capacity to reactivate PZAse-MT–Apo. An M. tuberculosis Rv2059 knockout strain
was Wayne positive and susceptible to PZA and did not have a signiﬁcantly different
POA efﬂux rate than the reference strain, although a trend toward a lower efﬂux
rate was observed after knockout. The metallochaperone Rv2059 restored the activ-
ity of metal-depleted PZAse in vitro. Although Rv2059 is important in vitro, it seems
to have a smaller effect on PZA susceptibility in vivo. It may be important to mecha-
nisms of action and resistance to pyrazinamide in M. tuberculosis. Further studies are
needed for conﬁrmation.
IMPORTANCE Tuberculosis is an infectious disease caused by the bacterium Myco-
bacterium tuberculosis and remains one of the major causes of disease and death
worldwide. Pyrazinamide is a key drug used in the treatment of tuberculosis, yet its
mechanism of action is not fully understood, and testing strains of M. tuberculosis
for pyrazinamide resistance is not easy with the tools that are presently available.
The signiﬁcance of the present research is that a metallochaperone-like protein may
be crucial to pyrazinamide’s mechanisms of action and of resistance. This may sup-
port the development of improved tools to detect pyrazinamide resistance, which
would have signiﬁcant implications for the clinical management of patients with tu-
berculosis: drug regimens that are appropriately tailored to the resistance proﬁle of
a patient’s individual strain lead to better clinical outcomes, reduced onward trans-
mission of infection, and reduction of the development of resistant strains that are
more challenging and expensive to treat.
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Tuberculosis (TB) is a disease affecting 10.0 million people globally each year (1) andremains one of the major causes of disease and death worldwide. It is exacerbated
by HIV-Mycobacterium tuberculosis coinfection (2) and by the emergence of multidrug-
resistant (MDR) and extensively drug-resistant (XDR) M. tuberculosis strains in both
industrialized and developing countries (2, 3).
Pyrazinamide (PZA) is a key drug used in the treatment of tuberculosis. Historically,
its inclusion in ﬁrst-line regimens enabled the duration of treatment to be shortened
and led to a reduction in relapse rates (4, 5). It is active against slowly dividing M.
tuberculosis bacteria and thus may be the most important drug in current and future TB
treatment regimens (6, 7). The emergence of strains resistant to PZA represents an
important public health problem, as PZA is a component of both ﬁrst- and second-line
treatment regimens. The number of patients with MDR TB, deﬁned as the presence of
resistance to both isoniazid and rifampin, is increasing globally (1), and additional
resistance to PZA among MDR-TB patients was estimated to have occurred in 480,000
patients with TB in 2015 (8). A recent Tanzanian study found that 15 of 30 (50%)
patients with MDR TB and 13 of 61 (21.3%) patients with drug-sensitive TB also had PZA
resistance (9). In 2015, the rates of PZA resistance among new cases of MDR TB in Peru
increased by 4%, and the percentage of MDR-TB cases with concomitant PZA resistance
was almost 60% (10).
The mechanisms of action and of resistance to PZA in M. tuberculosis are incom-
pletely understood. PZA is a prodrug that enters the mycobacteria by passive diffusion
and is transformed in the cytoplasm into pyrazinoic acid (POA) by a nicotinamidase that
also has nicotinamidase-pyrazinamidase (PZAse) activity (11). POA, the active drug, is
expelled from the bacilli by an efﬂux system yet to be identiﬁed. In the acidic
environment outside the bacilli, POA is protonated and then reenters the mycobacteria.
Once back inside the bacilli, the protons are released, acidifying the cytoplasm and
allowing POA to accumulate. This causes disruption in the mycobacterial membrane
permeability and transport, leading to cell death (12, 13).
PZAse/nicotinamidase is a ubiquitous metalloenzyme present in prokaryotes and
eukaryotes and expressed constitutively in M. tuberculosis (13, 14), Escherichia coli
(15–17), Salmonella enteritidis serovar Typhimurium (17), Torula cremoris (15), and
Borrelia burgdorferi (18). The physiological role of nicotinamidase is to convert
nicotinamide (NAD) to nicotinic acid mononucleotide. Adenylation of this mono-
nucleotide followed by amide formation completes the biosynthesis of NAD. NAD
and NAD phosphate (NADP) are essential compounds in over 300 biochemical
redox reactions (17).
It had previously been proposed that POA binds to the ribosomal protein RpsA and
that this inhibits trans translation, which is lethal to the mycobacteria (19). According
to this theory, PZA resistance may occur due to mutations in the RpsA C terminus that
prevent the binding of POA (19), and in keeping with this, Shi et al. recently identiﬁed
two mutations in the rpsA gene that were associated with PZA resistance (19). However,
other data are contradictory: a study evaluating the interaction between RpsA and POA
using isothermal titration calorimetry (ITC) found that deprotonation of POA in phos-
phate buffer was independent of RpsA (20).
Currently, the major mechanism of PZA resistance is thought to be loss of PZAse
activity and therefore failure to hydrolyze PZA into POA. Defective PZAse is frequently
found in PZA-resistant M. tuberculosis strains (14, 21–24), and several studies have
demonstrated an association between PZA resistance and mutations in the pncA gene,
which encodes PZAse (13, 14, 21–25). The same mechanism is responsible for the
natural PZA resistance of Mycobacterium bovis and Mycobacterium kansasii (26, 27). This
also suggests that pncA DNA sequencing could be used to predict resistance, provided
that it is possible to predict the effect of mutations on PZAse function. A recent study
that analyzed 10,209M. tuberculosis isolates found that sequencing correctly predicted
PZA resistance with 91.3% sensitivity and susceptibility with 96.8% speciﬁcity (28),
suggesting that additional factors besides pncA mutations are also present.
Although PZAse is constitutively expressed in M. tuberculosis, alterations in the level
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of pncA expression are known to affect PZA resistance, even among PZAse wild-type
strains (29, 30). Such alterations could impair intracellular PZAse activity and, as a
consequence, the POA efﬂux rate, resulting in PZA resistance. Mutations affecting pncA
expression include those affecting the pncA promoter and silent mutations that switch
codons, and they are associated with low levels of tRNA.
Important molecular characteristics of M. tuberculosis PZAse (PZAse-MT) have been
elucidated from crystallized homologous hydrolases, such as N-carbamoylsarcosine amido-
hydrolase (CHSase) from Arthrobacter (26% identical) (31), PZAse from Pyrococcus horikoshii
(37% identical) (32), and PZAse from Acinetobacter baumannii (37% identical) (33), as well
as from the recently crystallized structure of M. tuberculosis pyrazinamidase (34) and a
theoretical analysis of a modeled structure (35). According to these studies, the catalytic
cavity comprises an active site (D8, A134, and C138) and ametal-binding site (D49, H51, and
H71). Du et al. (32) showed that Zn2 was held in P. horikoshii PZAse crystals. Similarly, a
PZAse from A. baumannii cocrystallized with nicotinamide contained Zn2 and Fe2 in a
1:1 ratio (33), while the M. tuberculosis PZAse was successfully crystallized with Fe2 (34).
Metal ions are necessary for PZAse activity and have signiﬁcant implications for
PZA’s antibiotic mechanism of action (29, 32, 36–39). M. tuberculosis PZAse is inacti-
vated by the removal of divalent ions and can be differentially reactivated (i.e., enzyme
activity can be restored) (38, 40); Zhang et al. (38) observed reactivation by Fe2 and
Mn2 when analyzed by inductively coupled plasma-optical emission spectroscopy
(ICP-OES), and more recently, Sheen et al. (40) showed in vitro reactivation by Co2,
Mn2, and Zn2 but not Fe2, Fe3, or Mg2. In this study, atomic absorption and X-ray
ﬂuorescence assays showed Zn2 to be present in recombinant PZAse expressed in E.
coli (PZAse-EC), and 300 times as much Zn2 as enzyme was required for PZAse
reactivation. Based on these observations, the authors proposed that in vivo PZAse
obtains Zn2 ions through an assisted process with the intervention of a metallochap-
erone. This is further supported by the observation that intracellular concentrations of
proteins and metals exist at a ratio of 1:1 in vivo (41, 42).
A metallochaperone is a cellular transporter that delivers metal ions to proteins that
require metals for their functional activity. The roles of metallochaperones and metal
transporter proteins inM. tuberculosis, and speciﬁcally their relationships with antibiotic
resistance, have not been studied in detail. However, metallochaperones have been
described in other species (43), and their homologous proteins could similarly be
explored in M. tuberculosis.
Metallochaperones of the TroA superfamily, such as ZnuA, are involved in Zn2
importation by E. coli and other bacteria under low ion concentrations. This contributes
to the growth and pathogenicity of the bacterium (44, 45). ZnuA is a key component
of the ZnuABC zinc transporter, which has been well characterized (44–54). ZnuA
captures free Zn2 and delivers it to ZnuB, a transmembrane protein that carries Zn2
into the cytoplasm; this is mediated by ZnuC, which supplies the necessary energy to
complete the process (45).
In the recent annotation of the M. tuberculosis genome, Rv2059 was identiﬁed as a
Zn2 ABC-like transporter (55, 56) that may potentially facilitate interactions between
M. tuberculosis PZAse and its Zn2 metal cofactor.
In this study, we evaluated the hypothesis that ZnuA and its M. tuberculosis analog,
Rv2059, are necessary for PZAse activity in E. coli and M. tuberculosis, respectively. To
test this hypothesis, we measured the capacities of ZnuA and Rv2059 to facilitate the
reactivation of metal-depleted E. coli and M. tuberculosis PZAses, respectively.
RESULTS
Measurement of Zn2 content in ZnuA, ZnuA-Apo, and ZnuA-Tx by atomic
absorbance. The Zn2 content was found to be 10-fold lower in metal-depleted ZnuA
(ZnuA-Apo) than in either untreated ZnuA or heat-treated, EDTA-free ZnuA (ZnuA-Tx)
(0.98 M versus 11.11 M and 9.52 M, respectively) (Table 1).
Kinetic parameters of PZAse-EC. According to the linear regression model, for each
unit that the inverse of the substrate concentration increased, the inverse of the velocities
Metollachaperones Activate M. tuberculosis and E. coli PZAse Journal of Bacteriology
January 2020 Volume 202 Issue 2 e00331-19 jb.asm.org 3
 o
n
 January 16, 2020 at ST G
EO
RG
E'S LIBRARY
http://jb.asm.org/
D
ow
nloaded from
 
increased by 0.41 0.05mol min1 mg1. The kinetic parameters of the PZAse-EC were
as follows: Michaelis constant (Km), 0.36 0.12mM; catalytic constant (Kcat),
873.16 111.93min1; enzymatic activity, 42.74 8.12M POAmg PZAse1 min1; Vmax,
0.65 0.08mol min1 mg1; and enzymatic efﬁciency, 2,442.96 588.58mM1 min1,
with a 95% conﬁdence interval.
Reactivation of PZAse-EC–Apo with Zn2 and ZnuA. The enzyme activity of
metal-depleted inactivated E. coli PZAse (PZAse-EC–Apo) was increased by the addition
of both Zn2 and ZnuA. PZAse-EC–Apo treated with Zn2 reached 100% reactivation
(i.e., reached 100% of the enzymatic activity of untreated PZAse-EC) with 30 M Zn2
(79 M POA mg PZAse1 min1) (Fig. 1A). This showed a positive tendency when the
Zn2 concentration was increased, as determined by linear regression (P 0.0001).
PZAse-EC–Apo treated with ZnuA (200 M) was reactivated to a maximum of 65%
(44.7 M POA mg PZAse1 min1) (Fig. 1B). Restoration of enzyme activity occurred
with 40 M, 80 M, 100 M, and 200 M ZnuA, with corresponding activities of 26.1,
42.2, 39.1, and 44.7 M POA mg PZAse1 min1. ZnuA concentrations below 10 M did
not reactivate PZAse-EC–Apo. ZnuA showed a positive tendency in the reactivation of
PZAse-EC–Apo, as determined using linear regression (P 0.0001).
Reactivation of PZAse-MT–Apo with Zn2 and Rv2059. Metal-depleted inacti-
vated M. tuberculosis PZAse (PZAse-MT–Apo) treated with Zn2 reached 100% reacti-
vation with 10 M Zn2 (73.39 M POA mg PZAse1 min1) (Fig. 2A). PZAse-MT–Apo
reactivation showed a positive tendency with increasing Zn2 concentrations up to
100 M and a negative tendency thereafter, as determined using linear regression
(P 0.0001).
Concentrations of Rv2059 below 0.5 M failed to achieve reactivation of PZAse-MT–
Apo. At 0.5 M Rv2059, 16% of enzyme activity was recovered (8.8 M POA mg
PZAse1 min1), and with 1 M Rv2059, this reached 69% (47.8 M POA mg PZAse1
min1) (Fig. 2B).
Reactivation of PZAse-MT–Apo with ZnuA and ZnuA-Apo. PZAse-MT–Apo activ-
ity (7.4 M POA mg PZAse1 min1) increased with the addition of 1 M ZnuA to
26.5 M POA mg PZAse1 min1, which is equivalent to 55.4% of the activity achieved
by Rv2059 (47.8 M POA mg PZAse1 min1); 10 and 100 M ZnuA resulted in
activities of 51.7 and 75 M POA mg PZAse1 min1, respectively (Fig. 3A).
To test the resilience of the metallochaperone, the assay was repeated with 1 mM
phosphate buffer. PZAse-MT–Apo activity (7.4 M POA mg PZAse1 min1) increased
with the addition of 100, 300, and 500 M ZnuA, resulting in activities of 41, 47, and
64 M POA mg PZAse1 min1, respectively (Fig. 3B). The activity of PZAse-MT–Apo
was not affected by the addition of 1 or 10 M ZnuA when 1 mM phosphate buffer was
used, in contrast to reactivation under conditions of 50 mM phosphate buffer, which
showed increased reactivation with all ZnuA concentrations used. This suggests that a
structural factor is involved in the reactivation of PZAse-MT–Apo by ZnuA.
Under weak buffer conditions, ZnuA reactivated PZAse-MT–Apo to a greater extent
than ZnuA-Apo (P 0.0001): 100 M, 300 M, and 500 M ZnuA reactivated PZAse-
MT–Apo by 82%, 95%, and 135% more than ZnuA-Apo (Fig. 3B).
Effects of proteolytically inactivated ZnuA and Rv2059 on the reactivation of
metal-depleted PZAse-MT–Apo. Degradation of ZnuA and Rv2059 following proteo-
lytic treatment was veriﬁed by SDS-PAGE followed by staining with Coomassie brilliant
blue for ZnuA and silver nitrate for Rv2059.
TABLE 1 Concentrations of Zn2 present in 10 M (each) of the three protein variants
ZnuA, ZnuA-Apo, and ZnuA-Tx
Metallochaperone state (10 M) [Zn2] (M) [Zn2]/[protein] ratioa
ZnuA 11.11 1:1
ZnuA-Apo 0.98 1:10
ZnuA-Tx 9.52 1:1
aRatio of moles of Zn2 to moles of protein.
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(i) Comparison of the effects of proteolytically degraded ZnuA versus ZnuA on
recovered activity of PZAse-MT–Apo. ZnuA (2.5 M) led to an increase in PZAse-MT–
Apo activity by 66.6 M POA mg PZAse1 min1, whereas degraded ZnuA (2.5 M)
increased activity by 30.9 M POA mg PZAse1 min1. The activity recovered by
FIG 1 (A) Reactivation of PZAse-EC–Apo with Zn2. (B) Reactivation of PZAse-EC–Apo with ZnuA. The bars represent mean
estimated activity, and the whiskers represent 95% conﬁdence intervals.
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degraded ZnuA was similar to that generated by 2.5 M Zn2 (1.9 M POA mg
PZAse1 min1). Thermally inactivated proteinase K and ZnuA (2.5 M) increased
PZAse-MT–Apo activity to 73 M POA mg PZAse1 min1. The addition of inactive
proteinase K did not reduce reactivation (Fig. 4A).
FIG 2 (A) Reactivation of PZAse-MT–Apo with Zn2. (B) Reactivation of PZAse-MT–Apo with Rv2059. The bars represent mean
estimated activity, and the whiskers represent 95% conﬁdence intervals.
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(ii) Comparison of the effects of proteolytically degraded Rv2059 versus
Rv2059 on the capacity to recover activity of PZAse-MT–Apo. Rv2059 (1 M)
reactivated PZAse-MT–Apo activity to 24.8 M POA mg PZAse1 min1 and degraded
Rv2059 (1 M) to 12 M POA mg PZAse1 min1. The activity generated by 2.5 M
FIG 3 (A) Reactivation of PZAse-MT–Apo with ZnuA. (B) Reactivation of PZAse-MT–Apo with ZnuA and ZnuA-Apo. The bars
represent mean estimated activity, and the whiskers represent 95% conﬁdence intervals.
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FIG 4 (A) Reactivation of PZAse-MT–Apo with ZnuA versus degraded ZnuA. (B) Reactivation of PZAse-MT–Apo with Rv2059
versus degraded Rv2059. The colors represent different experimental conditions: red, PZAse-MT; blue, PZAse-MT–Tx; green,
PZAse-MT–Apo; orange, ZnuA or Rv2059; magenta, Zn; purple, proteolytically degraded ZnuA or Rv2059; and yellow, ZnuA or
Rv2059 and thermally inactivated proteinase K (iPk). The bars represent mean estimated activity, and the whiskers represent
95% conﬁdence intervals.
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Zn2 was 16 M POA mg PZAse1 min1. Thermally inactivated proteinase K with
Rv2059 reactivated PZAse-MT–Apo to 37.6 M POA mg PZAse1 min1. As observed
above, proteinase K did not reduce reactivation; on the contrary, trace concentrations
of ions conferred a boost to PZAse-MT–Apo activity (Fig. 4B).
Effect of thermal inactivation of ZnuA on reactivation of metal-depleted
PZAse-MT–Apo. PZAse-MT–Apo enzymatic activity was partially recovered by ther-
mally inactivated ZnuA: the reactivation of PZAse-MT–Apo by ZnuA treated with one
thermal shock was 30% less than when ZnuA without any treatment was used at the
same concentration, whereas reactivation by ZnuA that had been inactivated with
three thermal shocks was 43%. The Tris-HCl buffer-only control did not reactivate the
enzyme.
Structural model of ZnuA/Rv2059 and docking with PZAse-MT. The predicted
interactions between PZAse-MT and ZnuA or Rv2059 showed a favorable direct com-
munication with no sterical impediments between the metal-binding sites of the two
proteins. The distance between the metal-binding sites in the docking of ZnuA and
Rv2059 with PZAse was around 20 nm. Representatives of the highest-scoring struc-
tures from both clusters are shown in Fig. 5.
Wayne test, PZA susceptibility MIC, and POA efﬂux rate. The POA efﬂux rates for
the M. tuberculosis wild-type strain CDC1551 (0.023 M POA/h) and the CDC1551-
Rv2059-KO (knockout) strain (0.026 M POA/h) were not signiﬁcantly different (P 
0.27). No obvious difference was observed in the Wayne test or in MGIT (see below) PZA
susceptibility testing between the two strains. This indicates that the CDC1551-
FIG 5 (A) Possible binding between Rv2059 (top) and PZAse (bottom). The distance between the two
metallic clusters, shown as gray spheres, is 21 nm. (B) Possible binding between E. coli ZnuA (2OSV),
shown in red, and PZAse (3PL1), shown in blue. The distance between the metallic centers, shown as gray
spheres, is 20 nm.
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Rv2059-KO strain is no more resistant to PZA than the wild type, and therefore, in vivo
Rv2059 cannot be the only metallochaperone involved in the activation of PZAse.
DISCUSSION
This study demonstrates for the ﬁrst time that a metallochaperone-like protein
signiﬁcantly increased the enzymatic activity of M. tuberculosis PZAse in vitro. In our
experiments, the metallochaperone Rv2059 effected the reactivation of metal-depleted
PZAse fromM. tuberculosis. It may act in a similar manner in vivo, regulating intracellular
PZAse function, and may therefore play a crucial role in PZA’s mechanisms of action
and of resistance. As Rv2059 was shown not to be essential to PZAse activity in vivo, it
may be one of a number of metallochaperones with this function.
M. tuberculosis PZAse has nicotinamidase activity: it hydrolyzes nicotinamide to
nicotinic acid and ammonia in the b-NAD (NAD) salvage pathway (57). NAD modu-
lates antioxidation and oxidative stress, and the NADH/NAD ratio is a measure of
cellular reducing potential. Intracellular redox changes in M. tuberculosis have been
previously reported (58); cultures ofM. tuberculosis in the presence of certain antibiotics
were associated with a NADH/NAD ratio change of 2.65-fold compared to untreated
mycobacteria. Studies in mouse livers indicate that excessive intracellular NADH can
produce “reductive stress,” which may result from its capacity to induce the release of
ferrous iron from ferritin, an enzyme found in M. tuberculosis. Any evolutionary advan-
tage or biological role of PZAse as a monomer or homodimer in vivo might thus be
associated with its speciﬁc nicotinamidase activity (59). Therefore, it is likely that Rv2059
or other, similar metallochaperones may participate in activating the nicotinamidase
activity in vivo and thus regulate the intracellular reductive/oxidative stress.
Pyrazinamidase is a nonessential enzyme in NAD synthesis, despite having a fun-
damental role in NAD recycling, becauseM. tuberculosis presents high plasticity for NAD
synthesis. However, the NAD salvage pathway has been shown to be increased during
infection (57). This could be due to RV2059 capturing zinc ions from the extracellular
environment to activate PZAse.
As an active pyrazinamidase is fundamental to PZA susceptibility, mutated or
ineffective RV2059 or other, similar metallochaperones could be markers of PZA
resistance. On the other hand, supplementing PZA-resistant M. tuberculosis with
RV2059 (or other, similar metallochaperones) or zinc could possibly induce suscepti-
bility, assuming that the pncA gene has no mutations. Understanding this would have
signiﬁcant clinical consequences, as PZA is a key component of TB treatment regimens
and adequate tools to test for resistance are currently lacking.
The E. coli homologue ZnuA was also capable of reactivating PZAse-EC–Apo, but the
effect was far less potent than in M. tuberculosis: 10 to 20 times more ZnuA than
PZAse-EC–Apo was required to achieve reactivation, while Rv2059 was found to
reactivate PZAse-MT–Apo at a third of its concentration. This suggests that Rv2059
could have a “natural” metallochaperone function in the activation of PZAse in M.
tuberculosis, whereas ZnuA would not be expected to share this function in E. coli, as
such high concentrations are unlikely to occur in vivo.
Proteolytic-degradation assays conﬁrmed the importance of the structure of the
metallochaperone by showing that after proteolytic degradation, the capacity of
RV2059 to activate metal-depleted PZAse was greatly reduced. In fact, the activation
capacity of the proteolytically degraded Rv2059 was similar to that of the correspond-
ing equimolar concentration of free Zn2 that would have been released by the
degradation of the protein. This effect was observed in both the E. coli and the M.
tuberculosis metallochaperone/PZAse systems.
The fact that proteolytically degraded Rv2059 and ZnuA were able to reactivate
PZAse-MT–Apo similarly to an equivalent concentration of zinc suggests that these
metallochaperones coordinate zinc in equimolar concentrations. Conﬁrming this ﬁnd-
ing, the atomic absorbance analysis of ZnuA showed a Zn2/ZnuA ratio close to 1. In
addition, the three-dimensional (3D) structure models of ZnuA and Rv2059, which
comprise one His-His-Glu metal-binding site, as shown in other studies (50), also
Sheen et al. Journal of Bacteriology
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suggest a 1:1 Zn2/ZnuA molar ratio. The measured Zn2/ZnuA ratio that is close to 1
also suggests that it is unlikely that other metals could have been coordinated by these
metallochaperones during standard protein overexpression in E. coli when producing
the recombinant protein.
Based on the results obtained following metal depletion of ZnuA in the reactivation
of PZAse-MT–Apo, we conclude that the presence of Zn2 is necessary for ZnuA to
optimally reactivate PZAse-MT–Apo. This allows us to presume the existence of a
metallochaperone with a similar, as yet unreported role in the activity of PZAse in
tuberculosis.
According to the theoretical annotation of Rv2059, together with ZnuA, it belongs
to the group of proteins known as the TroA superfamily, which are transporters of Zn2
and Mn2 (55) and intervene in the importation of Zn2 by the ABC system (60). In
addition, ZnuA and Rv2059 are regulated by the Zur protein, which promotes the
transcription of both coding genes at low concentrations of Zn2 (49, 55, 61). The
sequence alignment between Rv2059 and ZnuA showed a conserved domain between
the histidines at positions 60 and 143 of ZnuA, which are involved in the coordination
of Zn2, and histidines at positions 137 and 197 of Rv2059.
Of note, ZnuA was highly thermoresistant. One thermal shock (100°C for 30 min)
only minimally affected the metallochaperone’s activity, but three consecutive thermal
shocks were able to reduce PZAse-MT–Apo reactivation to 43% compared to reactiva-
tion by untreated ZnuA (83%). This indicates that the function of ZnuA is not signiﬁ-
cantly altered by high temperatures, and it therefore possesses high structural stability,
which can be affected only by proteolytic enzymes such as proteinase K (22% reacti-
vation). Other studies have reported that the thermal stability of other metallochaper-
ones is increased in the presence of divalent ions (62).
Phosphate buffer conditions inﬂuence the recovery of PZAse activity mediated by
ZnuA. When reactivation of PZAse with ZnuA was evaluated under low-molarity buffer
conditions (0.8 to 1 mM), a small amount of PZAse-MT activity was recovered (Fig. 4),
but full PZAse-MT reactivation was achieved only with an optimum buffer concentra-
tion of 50 mM. Fifty millimolar buffer alone was not able to reactivate PZAse-MT–Apo,
precluding the possibility that the buffer itself contains traces of metal ions that are
able to reactivate PZAse.
It is known that variations in pH affect both the activity and the stability of an
enzyme (63). We believe that the low-molarity conditions during the reactivation of
PZAse-MT–Apo by ZnuA might not be enough to regulate the pH within a range for
proper structure/function for either or both PZAse and ZnuA.
Our results show that low concentrations of Zn2 (10 to 80 M) are capable of
optimally reactivating PZAse, which has never been shown before. It had previously
been reported (38, 40) that 1.5 mM Zn2 was the optimum concentration needed to
regain PZAse activity. However, that study did not evaluate as many points in the range
of 1 M to 2,000 M Zn2 as are reported here; the points that coincide with those in
this study are consistent. On the other hand, our results show that the reactivation of
PZAse-MT–Apo with Zn2 follows a nonlinear response and is reduced at Zn2
concentrations greater than 100 M.
Other studies have shown that metalloenzymes can be reactivated by metal cofac-
tors under saturating conditions with concentrations close to equimolar (64, 65), and
therefore, concentrations higher than 100 M Zn2 for 3 M PZAse may cause
oversaturation and loss of activity.
Our results provide evidence that the protein Rv2059 functions as a facilitator of
Zn2 for the activation of M. tuberculosis PZAse in vitro. Rv2059 may therefore be a
divalent cation metallochaperone that could participate in the mechanism of action of
PZA inM. tuberculosis but is not likely to participate in the mechanism of resistance. The
evaluation of Rv2059 activity in vivo using a knockout strain showed no alteration in
bacterial POA production. Thus, there may be multiple metallochaperones with effects
on PZAse activity similar to or perhaps even more potent than the action of Rv2059.
Other metallochaperones that play an important role in zinc homeostasis, particularly
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relating to the organism’s survival in the host, have been identiﬁed in other pathogenic
bacteria (66, 67). Regarding the possibility that Rv2059 (or other, similar metallochap-
erones) is an alternative drug target that could have an effect similar to that of PZA,
blocking Rv2059 with a speciﬁc drug would result in a less active PZAse and thus in PZA
resistance. However, other, similar metallochaperones may be involved in the activation
of essential metalloenzymes. In those cases, metallochaperones may constitute poten-
tially important drug targets. Further studies are needed to conﬁrm our ﬁndings and
also to further our understanding of the importance of metallochaperones to mecha-
nisms of mycobacterial resistance to PZA.
MATERIALS AND METHODS
Cloning of coding genes pncA from M. tuberculosis and E. coli, znuA from E. coli, and Rv2059
from M. tuberculosis. The M. tuberculosis and E. coli pncA, M. tuberculosis Rv2059, and E. coli znuA genes
were ampliﬁed by PCR using oligonucleotides with restriction sites for NcoI and XhoI. For the M.
tuberculosis H37Rv pncA gene, primer pair 5= CCC CCA TGG GCC GGG CGT TGA TCA TC and 5= CCC CTC
GAG GGA GCT GCA AAC CAA CTC was used to clone a 575-bp fragment. For the E. coli K-12 pncA gene,
primer pair 5= AAA CAT ATG CCC CCT CGC GC and 5= AAA CTC GAG CCC CTG TGT CTC TTC CC was used
to clone a 642-bp fragment. For the E. coli W3110 znuA gene, primer pair 5= AAA CAT ATG TTA CAT AAA
AAA ACG CTT CTT TTC G and 5= CCT CGA GAT CTC CTT TCA GGC AGC TC was used to clone a 933-bp
fragment. For the M. tuberculosis H37Rv Rv2059 gene, primer pair 5= CAT GCC ATG GGC AAA TCC GCC
ATC CAT C and 5= CGG CTC GAG AAG TGG CCG AAA GCG AG was used to clone a 1,350-bp fragment.
After ampliﬁcation and double digestion of the puriﬁed genes, the gene fragments were inserted into the
pET28a plasmid using T4 DNA ligase (NE BioLabs, Ipswich, MA) for 16 h at 16°C. For puriﬁcation, six
histidines were added to the carboxy-terminal end. E. coli NovaBlue cells (Novagen, San Diego, CA) were
transformed directly from the ligation reaction using a heat-based protocol (40). Plasmid DNA was
extracted using the QIAprep Spin Miniprep kit (Qiagen, Valencia, CA) and sequenced in an ABI Prism 3100
genetic analyzer (Applied Biosystem, Foster City, CA) in both directions to ensure that the gene was in
frame.
Production of the recombinant proteins PZAse-MT and PZAse-EC and ZnuA from E. coli. The
carboxy-terminal hexahistidine-tagged proteins PZAse-MT and PZAse-EC and ZnuA from E. coli were
expressed in BL21(DE3)(pLysS) cells (Novagen), as described previously (40). Isopropyl--D-
thiogalactoside was added to fresh overnight cultures at a ﬁnal concentration of 1 mM and incubated for
4 h at 37°C. Expression was conﬁrmed by SDSPAGE and Western blotting. The cells were harvested by
centrifugation at 4,830 g at 4°C for 10 min, followed by resuspension of the pellet in 20 ml binding
buffer (20 mM imidazole, 0.5 M NaCl, 20 mM phosphate buffer, pH 7.4). The suspension was frozen at
70°C and thawed at 37°C three times and then sonicated using a S3000 sonicator (Misonix, Farm-
ingdale, NY) at power level 3 for 3 cycles on ice. Each cycle was 1 min long, with alternating on/off
periods of 1 s each. The supernatant was centrifuged at 17,572 g at 4°C for 30 min and then loaded on
a 5-ml HisTrap (histidine-tagged) protein puriﬁcation column (Pharmacia, Piscataway, NJ) and washed
with 40 mM imidazole, 0.5 M NaCl, and 20 mM phosphate buffer, pH 7.4. Aliquots of the fractions
obtained were analyzed by SDS-PAGE and Western blotting. The primary antibody used for Western
blotting was mouse antiHis monoclonal antibody (MAb) (GenScript; A00186). Fractions containing pure
proteins were combined. The puriﬁed protein was concentrated 10 times and washed 3 times with
20 mM Tris-HCl, pH 7.9, by ﬁltration using cellulose membranes with a 10-kDa ﬁltering limit in an Ultracel
Amicon ultraﬁltration system (Millipore, Billerica, MA) at 4°C. The protein concentration was determined
by the Bradford method (68) or by bicinchoninic acid (BCA) protein assay using bovine serum albumin
(BSA) as a standard.
Expression of Rv2059 in our laboratory was unsuccessful; therefore, it was purchased from GenScript
(Piscataway, NJ). We received 1 ml of Rv2059 at a concentration of 0.6 mg/ml in PBS, pH 7.4. The purity
was 95%, according to SDS-PAGE and Western blot assays.
Kinetic parameters of PZAse-EC and PZAse-MT. The kinetic parameters of PZAse-EC were calcu-
lated using a modiﬁed PZA hydrolysis reaction (32). PZA at a range of concentrations (0 M to 10 M)
was incubated with 1 mM PZAse-EC in 50 mM sodium phosphate buffer, pH 6.5, for 1 min; 10 l of 20%
FeNH4(SO4)2 and 890 ml of 100 mM glycine-HCl buffer, pH 3.4, were added to stop the reaction, and the
optical density was measured at 450 nm in a 96-well plate. We calculated the Km to measure the afﬁnity
of PZAse for PZA, the Kcat, and the enzymatic efﬁciency (Eff) as Kcat/Km (69, 70). The enzyme activity was
estimated as the quantity of POA produced in a reaction of 1 min divided by the total quantity of
enzyme. The data were adjusted by linear regression to the Lineweaver-Burk plot (1/V versus 1/[S], where
V is the velocity of production of POA and [S] is the concentration of substrate PZA) and by nonlinear
regression to the Michaelis-Menten equation (71). The kinetic parameters of PZAse-MT have been
previously measured and reported by Sheen et al. (29).
Inactivation of PZAse-MT and PZAse-EC by metal depletion (chelation). Ions were removed from
the two PZAses using the chelating agent EDTA. PZAse (0.5 ml; 700 M) in phosphate buffer (100 mM;
pH 6.4) and EDTA (80 mM; pH 8) were incubated overnight at room temperature. PZAse without EDTA
was included as a chelation control. The EDTA was removed by 3 washes with 100 mM phosphate buffer,
pH 6.4, using ultraﬁltration until 1 ml of PZAse in the apoprotein state (PZAse-MT–Apo or PZAse-EC–Apo)
and 1 ml of PZAse control (PZAse-MT–Tx or PZAse-EC–Tx) were obtained. Aliquots of 500 l were stored
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at –20°C. The protein concentration was measured using the Bradford assay, and chelation was
conﬁrmed through a quantitative Wayne assay.
Chelation of ZnuA. ZnuA (2 ml; 400 M) was incubated in Tris-HCl (30 mM; pH 7) and EDTA (80 mM;
pH 8) overnight at 4°C. An EDTA-free control was also used. The samples were washed 3 times with
Tris-HCl (30 mM; pH 7) by ultraﬁltration until 1 ml of ZnuA in an apoprotein state (ZnuA-Apo) and 1 ml
of ZnuA with incubation treatment only (ZnuA-Tx) were obtained. The concentrations of the proteins
were measured using the Bradford assay, and 500-l aliquots were stored at 20°C.
Metal depletion of ZnuA was conﬁrmed by measuring the Zn2 concentrations in 10 ml of 10 M
ZnuA, ZnuA-Apo, and ZnuA-Tx in 30 mM Tris-HCl buffer, pH 7, using atomic absorption spectroscopy
(AAS). A standard curve was constructed using known quantities of ZnSO4·7H2O. A buffer-only control
was included to rule out the presence of the ion in the buffer.
Reactivation of metal-depleted PZAse-EC–Apo with Zn2 and ZnuA. PZAse-EC–Apo (3 M) was
incubated with concentrations of Zn2 (ZnSO4·7H2O) ranging from 0.1 M to 2,000 M or with ZnuA
metallochaperone at concentrations ranging from 0.5 M to 200 M for 30 min, with 50 mM phosphate
buffer. PZA (20 mM) was added, and after 3 min, the reaction was terminated with glycine-HCl, pH 3.4.
POA produced after the hydrolysis of PZA was revealed with ammonium ferrous sulfate, as described by
Sheen et al. (40). The absorbance of this modiﬁed Wayne assay (72) was read at 450 nm using a
spectrophotometer. Enzyme activity was then estimated as described above.
Reactivation of metal-depleted PZAse-MT–Apo with Zn2 and Rv2059. PZAse-MT–Apo (3 M)
was reactivated with increasing concentrations of Zn2 (ZnSO4·7H2O) ranging from 0.1 M to 1,000 M
Zn2 or with Rv2059 metallochaperone (0.1 M, 0.5 M, and 1 M) for 30 min, with 50 mM phosphate
buffer; 20 mM PZA was then added for 3 min. The reaction was stopped with glycine-HCl, pH 3.4, and
revealed with ammonium ferrous sulfate, as described above for PZAse-EC–Apo.
Reactivation of metal-depleted PZAse-MT–Apo using ZnuA and ZnuA-Apo. In order to evaluate
whether the E. coli metallochaperone ZnuA was also able to reactivate PZAse from M. tuberculosis, 3 M
PZAse-MT–Apo was titrated with ZnuA at concentrations of 200 M, 100 M, 10 M, and 1 M using the
method described above. In addition, to verify the importance of Zn2 to the reactivation capacity of
ZnuA, a reactivation assay was performed using ZnuA-Apo.
Next, we investigated whether the functional stability of ZnuA, previously tested in 50 mM phosphate
buffer at pH 6.4, was maintained under low-molarity buffer (1 mM). PZAse-MT–Apo (3 M) was titrated
in 0.8 to 1 mM phosphate buffer, pH 6.4, with ZnuA or ZnuA-Apo at concentrations of 500 M, 300 M,
100 M, 10 M, and 1 M. The activity for each of the reactions was measured quantitatively after
incubation for 30 min at 37°C.
Effects of proteolytically inactivated ZnuA and Rv2059 on reactivation of metal-depleted
PZAse-MT–Apo. For proteolytic degradation, the proteins were incubated with proteinase K (Ambion)
at 65°C for 4 h. Proteinase K was then itself inactivated by incubation at 120°C for 1 h. The proteinase
K/metallochaperone molar ratios used were 1:2,000 for ZnuA and 1:25 for Rv2059 for optimal degrada-
tion and inactivation. Protein degradation was veriﬁed by SDS-PAGE and revealed using Coomassie
brilliant blue for ZnuA and silver nitrate for Rv2059 due to its lower molecular weight. The absence of a
band of the corresponding molecular weight for each protein in the digested samples was considered
proof of degradation.
The degraded proteins and their active pairs were used to reactivate PZAse-MT–Apo in independent
Wayne assays as described above. A control consisting of inactivated proteinase K was added to the
active metallochaperones to exclude any decrease in reactivation caused by proteinase K.
Effect of thermally inactivated ZnuA in the reactivation of metal-depleted PZAse-MT–Apo.
ZnuA was thermally inactivated (denatured) using two methods. The ﬁrst method comprised one
thermal shock cycle of 100°C for 30 min followed by 1 min on ice, and the second consisted of three
thermal shock cycles at 120°C for 30 min each followed by 1 min on ice. Both methods used 100 l ZnuA
(125 M) in 1.5-ml vials. The thermally inactivated proteins were then evaluated in a Wayne reaction to
assess reactivation of PZAse-MT–Apo. A control consisting of 100 l 30 mM Tris-HCl buffer only was
included.
Structural model of ZnuA and Rv2059 and docking with PZAse-MT. The M. tuberculosis protein
Rv2059 structure was modeled with RaptorX (73) using as templates the Protein Data Bank (PDB)
structures 5KZJ, 5UXS, 1PQ4, 3HJT, and 5HX7, which correspond to YfeA (Yersinia pestis), AztC (Paracoccus
denitriﬁcans), an ABC transporter (Listeria monocytogenes), Lmb (Streptococcus agalactiae), and ZnuA
(Synechocystis sp.). The templates are metal-binding proteins that have been crystallized in complexes
with Zn or Mn. We predicted the structure of the region of the protein only from amino acids 38 to 304,
which corresponds to between 17 and 24% of the identity of the templates.
The PZAse and ZnuA crystal structures were obtained from the PDB (IDs 3PL1 and 2OSV) (30, 50).
Protein-protein docking was performed using the HADDOCK Web server (73) to model the heterodimer
structure of PZAse in complex with Rv2059. We deﬁned the residues involved in metal binding as active
residues to guide the protein-protein docking. In the case of Rv2059, the metal-binding residues were
H75, H135, and E199, as predicted using the NCBI Conserved Domain Database (74). The metal-binding
residues on the PZAse (PDB ID 3PL1) were D49, H51, H57, and H71 (34), and for E. coli ZnuA (PDB ID
2OSV), the residues were E77, H78, H161, and H225 (50).
Wayne test. The Wayne test is a colorimetric method that detects POA that is released by bacilli into
the culture medium (72). The test was performed as described by P. T. Kent (75). Based on the color
intensity, the selected strains were classiﬁed as having a positive, weak, or negative Wayne activity. Both
the CDC1551 and CDC1551-RV2059-KO strains were tested in duplicate for each strain.
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Measurement of POA efﬂux by quantitative Wayne test. The production of POA by M. tuberculosis
strains CDC1551 and CDC1551-Rv2059-KO (obtained through BEI Resources) was measured using the
Wayne assay in citrate buffer, pH 7.0, as described previously (76). For each strain, 3 inoculation loops of
culture were resuspended in 500 l of citrate buffer and disaggregated with 2.5-mm beads by vortex
agitation. Then, 20 l of cell suspension was added to 5 ml of citrate buffer, pH 7.0, in triplicate until
McFarland scale 4 turbidity was obtained. Pyrazinamide (400 g/ml) was then added to the suspension.
Each sample was harvested 6 times at 12-h intervals. During each harvest, cells were collected from
500 l of sample by centrifugation at 13,000 rpm for 10 min; the supernatant was recovered, inactivated
at 95°C for 20 min, and stored at20°C. It was then incubated at 37°C with constant agitation (300 rpm).
The presence of POA was revealed by adding 10% ferrous ammonium sulfate and measured at 450 nm.
Comparative Bactec MGIT measurement. The Bactec MGIT 960 assay is an automated assay that
is used to evaluate M. tuberculosis growth and that also provides information on PZA susceptibility. The
assay was performed according to standard guidelines. Brieﬂy, a loopful of M. tuberculosis culture grown
on solid 7H10 medium was suspended in a tube containing beads of 1-mm diameter. This was vortexed
and incubated for 20 min, and the bacterial suspension was transferred to a separate tube, where its
turbidity was adjusted to a 0.5 McFarland standard equivalent. Dilutions (1:5 and 1:50) were then
prepared using saline solution, and 500 l was added to 7H9 medium supplemented with oleic
acid-albumin-dextrose-catalase (OADC), with and without 100 g/ml PZA. The tubes were incubated in
the Bactec MGIT 960 instrument. A ﬁnal readout representing the ratio between the ﬂuorescences of the
strain in the presence and absence of PZA was taken to indicate whether the strain was sensitive or
resistant to PZA.
Statistical analysis. The effects of the treatment (Zn2, ZnuA, ZnuA-Apo, or Rv2059) on the activity
of PZAse-EC–Apo and PZAse-MT–Apo were calculated using a multiple-linear-regression model, includ-
ing an interaction term. Statistical analysis was performed under 5% signiﬁcance using the statistical
package Stata 13.0.
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